Table 4.
Multivariate analyses of inflammatory and clinical characteristics in relation to 5-year DMFS in the study population (n = 217).
| Variable | HR | 95% CI | p-Value | Variable | HR | 95% CI | p-Value |
|---|---|---|---|---|---|---|---|
| NLR | MLR | ||||||
| High | 0.84 | 0.44–1.59 | 0.59 | High | 0.44 | 0.22–0.86 | 0.02 |
| Low | Ref. | Low | Ref. | ||||
| Age at diagnosis | 0.99 | 0.96–1.02 | 0.56 | Age at diagnosis | 0.99 | 0.96–1.02 | 0.42 |
| Clinical tumor stage (cT) | Clinical tumor stage (cT) | ||||||
| 1 | 0.18 | 0.05–0.65 | 0.01 | 1 | 0.18 | 0.05–0.62 | 0.01 |
| 2 | 0.22 | 0.11–0.43 | <0.0001 | 2 | 0.18 | 0.09–0.36 | <0.0001 |
| 3-4 | Ref. | 3-4 | Ref. | ||||
| Clinical node stage (cN) | Clinical node stage (cN) | ||||||
| cN0 | 0.43 | 0.23–0.83 | 0.01 | cN0 | 0.46 | 0.24–0.89 | 0.02 |
| cN+ | Ref. | cN+ | Ref. | ||||
| Ki67 at core biopsy | Ki67 at core biopsy | ||||||
| ≤14% | 0.59 | 0.29–1.22 | 0.15 | ≤14% | 0.45 | 0.21–0.97 | 0.04 |
| >14% | Ref. | >14% | Ref. | ||||
| Grading at biopsy | Grading at biopsy | ||||||
| I-II | 4.84 | 1.84–12.75 | 0.001 | I-II | 4.03 | 1.52–10.68 | 0.01 |
| III | Ref. | III | Ref. | ||||
| Histological type at biopsy | Histological type at biopsy | ||||||
| Ductal | 0.73 | 0.31–1.74 | 0.48 | Ductal | 0.62 | 0.27–1.42 | 0.26 |
| Lobular | Ref. | Lobular | Ref. | ||||
| Biological portrait | Biological portrait | ||||||
| ER+/HER2- | 0.47 | 0.21–1.06 | 0.07 | ER+/HER2- | 0.49 | 0.21–1.11 | 0.09 |
| ER+/HER2+ | 0.28 | 0.08–1 | 0.05 | ER+/HER2+ | 0.36 | 0.1–1.27 | 0.11 |
| ER-/HER2+ | 0.85 | 0.16–4.58 | 0.85 | ER-/HER2+ | 0.91 | 0.17–4.91 | 0.91 |
| ER-/HER2- | Ref. | ER-/HER2- | Ref. | ||||
| NACT regimen | NACT regimen | ||||||
| Type 1 | 0.73 | 0.15–3.6 | 0.70 | Type 1 | 0.86 | 0.17–4.27 | 0.85 |
| Type 2 | 1.44 | 0.31–6.72 | 0.64 | Type 2 | 1.75 | 0.37–8.16 | 0.48 |
| Type 3 | 0.58 | 0.09–3.92 | 0.57 | Type 3 | 0.49 | 0.07–3.35 | 0.47 |
| Others | Ref. | Others | Ref. | ||||
| PLR | PIV | ||||||
| High | 0.92 | 0.49–1.74 | 0.80 | High | 0.81 | 0.41–1.6 | 0.55 |
| Low | Ref. | Low | Ref. | ||||
| Age at diagnosis | 0.99 | 0.96–1.02 | 0.52 | Age at diagnosis | 0.99 | 0.96–1.02 | 0.52 |
| Clinical tumor stage (cT) | Clinical tumor stage (cT) | ||||||
| 1 | 0.18 | 0.05–0.65 | 0.01 | 1 | 0.18 | 0.05–0.65 | 0.01 |
| 2 | 0.22 | 0.11–0.43 | <0.0001 | 2 | 0.21 | 0.11–0.42 | <0.0001 |
| 3-4 | Ref. | 3-4 | Ref. | ||||
| Clinical node stage (cN) | Clinical node stage (cN) | ||||||
| cN0 | 0.42 | 0.22–0.8 | 0.01 | cN0 | 0.43 | 0.23–0.82 | 0.010 |
| cN+ | Ref. | cN+ | Ref. | ||||
| Ki67 at core biopsy | Ki67 at core biopsy | ||||||
| ≤14% | 0.59 | 0.29–1.22 | 0.15 | ≤14% | 0.58 | 0.28–1.21 | 0.15 |
| >14% | Ref. | >14% | Ref. | ||||
| Grading at biopsy | Grading at biopsy | ||||||
| I-II | 4.98 | 1.89–13.07 | 0.001 | I-II | 4.90 | 1.86–12.87 | 0.001 |
| III | Ref. | III | Ref. | ||||
| Histological type at biopsy | Histological type at biopsy | ||||||
| Ductal | 0.68 | 0.3–1.56 | 0.36 | Ductal | 0.66 | 0.29–1.52 | 0.33 |
| Lobular | Ref. | Lobular | Ref. | ||||
| Biological portrait | Biological portrait | ||||||
| ER+/HER2- | 0.46 | 0.2–1.05 | 0.07 | ER+/HER2- | 0.45 | 0.2–1.03 | 0.06 |
| ER+/HER2+ | 0.28 | 0.08–0.97 | 0.04 | ER+/HER2+ | 0.29 | 0.08–1.01 | 0.05 |
| ER-/HER2+ | 0.84 | 0.15–4.59 | 0.84 | ER-/HER2+ | 0.85 | 0.16–4.56 | 0.85 |
| ER-/HER2- | Ref. | ER-/HER2- | Ref. | ||||
| NACT regimen | NACT regimen | ||||||
| Type 1 | 0.73 | 0.15–3.63 | 0.70 | Type 1 | 0.72 | 0.14–3.55 | 0.68 |
| Type 2 | 1.47 | 0.31–6.91 | 0.63 | Type 2 | 1.48 | 0.32–6.91 | 0.62 |
| Type 3 | 0.60 | 0.09–4.04 | 0.60 | Type 3 | 0.55 | 0.08–3.81 | 0.54 |
| Others | Ref. | Others | Ref. |